A compound that science had not yet identified
In the mountain markets of Yunnan, China, an ordinary-looking mushroom has long carried an extraordinary secret: those who eat it undercooked begin to see tiny people moving through their world. Scientists at the University of Utah have now confirmed that Lanmaoa asiatica produces these vivid Lilliputian hallucinations through no known chemical pathway — no psilocybin, no ibotenic acid — suggesting that nature has quietly invented a psychoactive compound entirely unknown to pharmacology. The discovery reminds us that the living world still holds mechanisms of mind and perception that human science has yet to name.
- Yunnan hospitals treat dozens of patients each year who arrive disoriented and describing the same impossible vision: small, detailed human figures moving through their peripheral sight after eating undercooked Lanmaoa asiatica mushrooms.
- When mycologists sequenced 53 mushroom genomes searching for the genetic signatures of known hallucinogens, they found nothing — the mushroom was producing profound perceptual distortions through a mechanism science had never catalogued.
- The symptom profile — dizziness, auditory hallucinations, physical sickness, and miniature visions — differs sharply from psilocybin or ibotenic acid poisoning, leaving treating physicians without a clear pharmacological map for what they are confronting.
- Researchers identified 17 Lanmaoa species, including four previously unnamed, giving the genus its first comprehensive genomic foundation and offering a more reliable tool for distinguishing edible from dangerous lookalikes in markets and fields.
- The unknown metabolite responsible for the hallucinations now stands as one of pharmacology's more intriguing open questions, with its eventual identification potentially illuminating how the human brain constructs visual reality itself.
In the markets of Yunnan, a mushroom called Lanmaoa asiatica — known locally as jian shou qing — sits among ordinary produce with an unremarkable appearance. But eaten undercooked, it transforms the world: tiny, vivid human figures appear and move through the consumer's vision. Clinically, these are called Lilliputian hallucinations, named after the miniature inhabitants of Swift's fictional island. Yunnan hospitals see dozens of such cases every year.
The scientific assumption had always been simple — a hallucinogenic mushroom must contain a known hallucinogen. But when mycologists Colin Domnauer and Bryn Dentinger of the University of Utah sequenced the genomes of 53 Lanmaoa specimens, they found no genetic signatures for psilocybin or ibotenic acid. The biosynthetic pathways for both well-studied compounds were simply absent. Whatever was sending people into visions of tiny humans was something pharmacology had not yet named.
The effects go beyond the visual. Consumers also report dizziness, auditory hallucinations, and physical illness — a symptom profile distinct enough from known mushroom poisons to confirm that an entirely novel metabolite is at work. This distinction matters practically: doctors treating poisoning cases need to understand what they are dealing with, and currently, that substance has no entry in the scientific literature.
The genome work produced a second significant finding. By mapping 1,515 corresponding genes across specimens, the researchers clarified the boundaries of the Lanmaoa genus itself, identifying 17 recognized species — including four newly named ones, among them Lanmaoa fallax and Lanmaoa carbonilivor. Because Lanmaoa mushrooms share many physical traits and are traded commercially around the world, this genetic clarity offers a more reliable foundation for distinguishing safe species from dangerous lookalikes, a genuine public health benefit.
The mystery compound remains unidentified, but the research has opened a path. When it is eventually isolated, it may offer not only a new pharmacological entry but a window into how the human brain generates visual hallucinations and constructs perception itself — a reminder that the living world still holds mechanisms of mind that science has yet to fully encounter.
In Yunnan's markets, a mushroom sits among the ordinary produce with an extraordinary secret. Lanmaoa asiatica, called jian shou qing locally, looks unremarkable enough. But when someone eats it undercooked, the world transforms. Tiny people materialize in their vision—not as a fleeting impression but as vivid, detailed figures moving through space. The condition has a clinical name: Lilliputian hallucinations, named after the miniature inhabitants of Jonathan Swift's fictional island. Yunnan's hospitals see dozens of these cases each year, patients arriving disoriented, describing the same impossible sight.
For years, the assumption was straightforward. A mushroom that produces hallucinations must contain one of the known hallucinogenic compounds—psilocybin, perhaps, or ibotenic acid. These are the chemicals that have been studied, mapped, understood. But when Colin Domnauer and Bryn Dentinger, mycologists at the University of Utah, decided to investigate, they found something unexpected. They sequenced the genomes of 53 mushroom samples from across the wider Lanmaoa genus, specifically looking for the genetic signatures that would produce psilocybin or ibotenic acid. The genes simply weren't there. The mushroom was causing vivid hallucinations through some other mechanism entirely—one that science had not yet identified.
The absence of known hallucinogenic pathways pointed to a startling conclusion: Lanmaoa asiatica must contain a novel compound, something entirely new to pharmacology. The researchers wrote in their published findings that despite the reported hallucinations, they found no close matches to genes associated with either of the two well-known mushroom hallucinogens. The biosynthetic pathways they examined turned up nothing. Whatever was causing people to see tiny humans moving through their peripheral vision, it was not a substance already catalogued in the scientific literature.
The hallucinations are not the only effect. People who consume undercooked Lanmaoa asiatica report dizziness, auditory hallucinations, and physical sickness alongside the visions. The symptom profile differs markedly from what psilocybin or ibotenic acid poisoning produces, further evidence that an unknown metabolite was at work. This distinction matters not just for understanding the mushroom itself, but for treating the people who eat it. Doctors in Yunnan needed to know what they were dealing with, and the answer was: something without a name.
The genome sequencing work yielded another significant finding. By identifying 1,515 corresponding genes across the selected specimens, Domnauer and Dentinger clarified what actually defines membership in the Lanmaoa genus. The mushrooms in this family share many physical characteristics, making them difficult to distinguish in the field or at market. But their genetic signatures told a different story. The researchers identified 17 recognized species in the genus, including four that had not been formally identified before. Two of these newly named species were Lanmaoa fallax and Lanmaoa carbonilivor. The work suggested that some existing specimens might need reclassification, and that the evolutionary tree of the genus could now be mapped more completely.
This taxonomic clarity addresses a serious public health concern. Lanmaoa species are popular commercial products traded globally, and misidentification of wild edible mushrooms with poisonous lookalikes is a well-documented hazard. People gathering mushrooms in the field cannot always tell the difference between safe and dangerous species. Better genetic understanding provides a foundation for more reliable identification, protecting both consumers and the medical practitioners who treat poisoning cases.
The mystery of what compound causes the tiny-people hallucinations remains unsolved, but the research has created a pathway forward. Once scientists identify the novel metabolite, they may unlock insights into how the human brain generates visual hallucinations and processes perception itself. The Lanmaoa genus, long overlooked, has become a window into both pharmacology and neuroscience. The researchers note that their work establishes a comprehensive genomic foundation for future investigation into the evolutionary history and secondary chemistry of the genus—a foundation that could reshape understanding of how mushrooms produce bioactive compounds, and what those compounds might teach us about ourselves.
Notable Quotes
Biosynthetic gene mining of the L. asiatica genome found no close hits with any genes known in the production of mushroom psychoactive compounds— University of Utah researchers Domnauer and Dentinger
The phylogeny and genomic data provided in this study may support future drug discovery efforts, as well as research into the evolution and phylogenetic distribution of the potentially important bioactive secondary chemistry within the genus Lanmaoa— The researchers
The Hearth Conversation Another angle on the story
Why does this mushroom produce hallucinations of tiny people specifically? Why not other visions?
That's the question no one can answer yet. The hallucinations are consistent enough that they have a clinical name, but the mechanism is completely unknown. It's as if the mushroom has learned to speak directly to a very particular part of human perception.
So the researchers ruled out the usual suspects—psilocybin, ibotenic acid. What does that tell us?
It tells us the mushroom is doing something genuinely novel. It's not just another variation on a known hallucinogen. There's a compound in there that science hasn't catalogued, hasn't named, hasn't studied. That's rare.
How many people are actually affected by this each year?
Yunnan hospitals treat dozens of cases annually. That's enough to be a real public health issue, but not so many that it's grabbed global attention. Most people outside China have never heard of it.
The researchers also reclassified the mushroom species themselves. Why does that matter?
Because these mushrooms look almost identical to each other. You can't tell them apart by eye. But genetically, they're distinct. If you're a forager or a doctor trying to figure out what someone ate, that distinction is everything. Misidentification can be fatal.
What happens next? Does identifying the compound change anything for the people getting sick?
It could. Once you know what the compound is, you can study how it works in the brain, how to treat poisoning, maybe even whether it has medical applications. Right now, doctors are treating symptoms without understanding the cause.
Is there any chance this compound could be useful?
That's what the researchers hint at. They mention future drug discovery efforts. A compound that produces such specific, vivid hallucinations might teach us something about perception itself—or it might become a tool for understanding certain neurological conditions. But that's speculation. First, you have to find it.